Rina Kennedy

Rina Kennedy is a seasoned professional in biopharmaceutical development, currently serving as a Senior Principal Associate in CMC Program Management at Eisai US since May 2020. In this role, Rina supports Drug Substance CMC activities, including project scheduling and resource management across various critical areas such as Cell Banking and Regulatory Submissions. Prior to this position, Rina held multiple roles at Eisai US, contributing to monoclonal antibody research focused on oncology while also managing CMC activities. Rina's extensive experience at Morphotek, Inc. spans nearly two decades, where Rina advanced from a Research Technician to Senior Scientist in Immunotherapy Development. Rina holds a degree from the University of Pittsburgh.